

## ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 27 JUNE 2024

### Availability of preliminary documents

**Chassieu (France), May 23, 2024 – 6:00pm**

Amoéba shareholders are invited to attend the Ordinary and Extraordinary General Meeting to be held on June 27, 2024 at 9 a.m. at the Company's office at 38 avenue des frères Montgolfier, 69680 Chassieu.

The notice of meeting, including the agenda and draft of the resolutions, was published in the BALO (Bulletin des Annonces Légales Obligatoires) on May 22, 2024.

The documents and information provided for in articles R. 22-10-23, L. 225-115 and R. 225-83 of the French Commercial Code are available to shareholders from the time the General Meeting is convened, in accordance with the applicable regulations, and are published on the Company's website at <https://amoeba-nature.com/investisseur/assemblee-generale>.

For information, electronic voting via the VOTACCESS secure voting platform for the Annual General Meeting of June 27, 2024 will be open from June 7 until June 26, 2024 at 3:00 p.m. (Paris time).

Shareholders wishing to use this platform can consult the access details in the notice of meeting and on the company's website.

---

### **About AMOÉBA:**

Founded in 2010, Amoéba is a biotech based in Chassieu (Lyon, France) with the ambition to become a major player for the treatment of microbiological risk in the water, crop protection and cosmetic sectors.


Based on the natural properties of a unique, exclusively patented, microorganism, the only one of its kind in the world, our biological solutions offer a viable alternative to the chemical products that are widely used in the industry today. Amoéba is currently focused on the global biocontrol market for plant protection and the cosmetics market. As the market release of phytosanitary products is subject to local regulatory approvals, the Company has completed the regulatory processes required and in 2022 obtained approval for its active substance in the United States and its recommendation for approval in Europe, issued by the Austrian authority. As the cosmetic application does not require prior approval from a relevant authority in Europe and the United States, the party responsible for bringing the formulated cosmetic product to market must carry out a self-assessment of its safety.

Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit [www.amoeba-nature.com](http://www.amoeba-nature.com).

### **Contacts:**

#### **Amoéba**

Jean-François Doucet  
Chief Executive Officer


 +33 (0)4 26 69 16 00

 [jf.doucet@amoeba-nature.com](mailto:jf.doucet@amoeba-nature.com)

#### **Calyptus**

*Investor & Press Relations*

Nicolas Hélin / Mathieu Calleux

 +33 (0)1 53 65 37 90 / 91

 [amoeba@calyptus.net](mailto:amoeba@calyptus.net)

### **Disclaimer**

*This press release contains certain forward-looking statements concerning AMOÉBA which are based on its own assumptions and estimates and on information that is currently available to us. However, AMOÉBA gives no assurance that the estimates contained in such forward-looking statements will be verified, with these estimates subject to numerous risks, including the risks set forth in AMOÉBA's universal registration document filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 29, 2024 under number D24-0352 and available on the AMOÉBA website ([www.amoeba-nature.com](http://www.amoeba-nature.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOÉBA or not currently considered material by AMOÉBA. The occurrence of all or part of such risks could cause AMOÉBA's actual results, financial conditions, performance, or achievements to be materially different from such forward-looking statements.*